Autoimmune NMDA receptor encephalitis

Clinica Chimica Acta

Volumn 438, Issue , 2015, Pages 90-97

  Lazar Molnar, Eszter ^a,b   Tebo, Anne E ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

Author keywords

Autoantibody; Encephalitis; NMDA receptor; Psychosis

Indexed keywords

ALEMTUZUMAB; AUTOANTIBODY; BENZODIAZEPINE; DIPHENHYDRAMINE; HALOPERIDOL; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; AMPHIPHYSIN; BENZODIAZEPINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; NEUROLEPTIC AGENT; NEUTROPHIL CYTOPLASMIC ANTIBODY; RITUXIMAB;

ABNORMAL BEHAVIOR; AGE DISTRIBUTION; ALLERGIC ENCEPHALITIS; ALLERGIC ENCEPHALOMYELITIS; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ATTENTION DEFICIT DISORDER; BEHAVIOR CHANGE; BRAIN INFECTION; BREATHING DISORDER; CATATONIA; CLINICAL FEATURE; DEPRESSION; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DYSTONIA; ELECTROCONVULSIVE THERAPY; EMOTIONAL DISORDER; FEVER; GENDER; HEADACHE; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; MALAISE; MEMORY DISORDER; MENINGITIS; METABOLIC ENCEPHALOPATHY; NAUSEA; NEOPLASM; PARANOIA; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEIZURE; SYMPTOMATOLOGY; VASCULAR DISEASE; AUTOIMMUNE DISEASE; CHEMISTRY; ENCEPHALITIS; FEMALE; IMMUNOLOGY; MALE; PHYSIOLOGY; ANTIBODY SPECIFICITY; AUTOIMMUNITY; AUTONOMIC DYSFUNCTION; BIPOLAR DISORDER; BRAIN TUMOR; BRAIN VASCULITIS; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE SEVERITY; EPILEPSY; IMMUNOTHERAPY; MAJOR DEPRESSION; MEMORY; MUSCLE RIGIDITY; NERVE CELL PLASTICITY; NEUROPATHOLOGY; PATIENT MONITORING; PROTEIN FUNCTION; SCHIZOAFFECTIVE PSYCHOSIS; TREATMENT INDICATION;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; ENCEPHALITIS; FEMALE; HUMANS; MALE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84906739379     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.08.010     Document Type: Review

References (57)

1. Dalmau J., Tuzun E., Wu H.Y., et al. Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007, 61:25-36.
2. Gable M.S., Sheriff H., Dalmau J., Tilley D.H., Glaser C.A. The frequency of autoimmune N-methyl-d-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 2012, 54:899-904.
3. Steiner J., Walter M., Glanz W., et al. Increased prevalence of diverse N-methyl-d-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-d-aspartate glutamate receptor encephalitis. JAMA Psychiatry 2013, 70:271-278.
4. Tsutsui K., Kanbayashi T., Tanaka K., et al. Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. BMC Psychiatry 2012, 12:37.
5. Lennox B.R., Coles A.J., Vincent A. Antibody-mediated encephalitis: a treatable cause of schizophrenia. Br J Psychiatry 2012, 200:92-94.
6. Traynelis S.F., Wollmuth L.P., McBain C.J., et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 2010, 62:405-496.
7. Furukawa H., Singh S.K., Mancusso R., Gouaux E. Subunit arrangement and function in NMDA receptors. Nature 2005, 438:185-192.
8. MacDermott A.B., Mayer M.L., Westbrook G.L., Smith S.J., Barker J.L. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. Nature 1986, 321:519-522.
9. Cull-Candy S., Brickley S., Farrant M. NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 2001, 11:327-335.
10. Kalia L.V., Kalia S.K., Salter M.W. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 2008, 7:742-755.
11. Viaccoz A., Desestret V., Ducray F., et al. Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology 2014, 82:556-563.
12. Gianani R., Sarvetnick N. Viruses, cytokines, antigens, and autoimmunity. Proc Natl Acad Sci U S A 1996, 93:2257-2259.
13. Armangue T., Leypoldt F., Malaga I., et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 2014, 75:317-323.
14. Hacohen Y., Deiva K., Pettingill P., et al. N-methyl-d-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov Disord 2014, 29:90-96.
15. Leypoldt F., Titulaer M.J., Aguilar E., et al. Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: case report. Neurology 2013, 81:1637-1639.
16. Armangue T., Titulaer M.J., Malaga I., et al. Pediatric anti-N-methyl-d-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr 2013, 162:850-856. [e852].
17. De Tiege X., Rozenberg F., Des Portes V., et al. Herpes simplex encephalitis relapses in children: differentiation of two neurologic entities. Neurology 2003, 61:241-243.
18. Dalmau J., Gleichman A.J., Hughes E.G., et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008, 7:1091-1098.
19. Hughes E.G., Peng X., Gleichman A.J., et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010, 30:5866-5875.
20. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20:201-225.
21. Weiner A.L., Vieira L., McKay C.A., Bayer M.J. Ketamine abusers presenting to the emergency department: a case series. J Emerg Med 2000, 18:447-451.
22. Mohn A.R., Gainetdinov R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999, 98:427-436.
23. Irani S.R., Bera K., Waters P., et al. N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010, 133:1655-1667.
24. Martinez-Hernandez E., Horvath J., Shiloh-Malawsky Y., Sangha N., Martinez-Lage M., Dalmau J. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology 2011, 77:589-593.
25. Dalmau J., Lancaster E., Martinez-Hernandez E., Rosenfeld M.R., Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011, 10:63-74.
26. Iizuka T., Sakai F., Ide T., et al. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology 2008, 70:504-511.
27. Peery H.E., Day G.S., Dunn S., et al. Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmun Rev 2012, 11:863-872.
28. Suh-Lailam B.B., Haven T.R., Copple S.S., Knapp D., Jaskowski T.D., Tebo A.E. Anti-NMDA-receptor antibody encephalitis: performance evaluation and laboratory experience with the anti-NMDA-receptor IgG assay. Clin Chim Acta 2013, 421:1-6.
29. Titulaer M.J., McCracken L., Gabilondo I., et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013, 12:157-165.
30. Titulaer M.J., Dalmau J. Seizures as first symptom of anti-NMDA receptor encephalitis are more common in men. Neurology 2014, 82:550-551.
31. Gresa-Arribas N., Titulaer M.J., Torrents A., et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014, 13:167-177.
32. Hacohen Y., Wright S., Waters P., et al. Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry 2013, 84:748-755.
33. Venkatesan A., Tunkel A.R., Bloch K.C., et al. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin Infect Dis 2013, 57:1114-1128.
34. Solomon T., Michael B.D., Smith P.E., et al. Management of suspected viral encephalitis in adults-Association of British Neurologists and British Infection Association National Guidelines. J Infect 2012, 64:347-373.
35. Britton P.N., Dale R.C., Booy R., Jones C.A. Acute encephalitis in children: progress and priorities from an Australasian perspective. J Paediatr Child Health 2014, (in press). 10.1111/jpc.12650.
36. Malter M.P., Elger C.E., Surges R. Diagnostic value of CSF findings in antibody-associated limbic and anti-NMDAR-encephalitis. Seizure 2013, 22:136-140.
37. Bien C.G., Vincent A., Barnett M.H., et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012, 135:1622-1638.
38. Gleichman A.J., Spruce L.A., Dalmau J., Seeholzer S.H., Lynch D.R. Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain. J Neurosci 2012, 32:11082-11094.
39. Hansen H.C., Klingbeil C., Dalmau J., Li W., Weissbrich B., Wandinger K.P. Persistent intrathecal antibody synthesis 15years after recovering from anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol 2013, 70:117-119.
40. Vincent A., Bien C.G., Irani S.R., Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011, 10:759-772.
41. Deakin J., Lennox B.R., Zandi M.S. Antibodies to the N-methyl-d-aspartate receptor and other synaptic proteins in psychosis. Biol Psychiatry 2014, 75:284-291.
42. Haberlandt E., Bast T., Ebner A., et al. Limbic encephalitis in children and adolescents. Arch Dis Child 2011, 96:186-191.
43. van Coevorden-Hameete M.H., de Graaff E., Titulaer M.J., Hoogenraad C.C., Sillevis Smitt P.A. Molecular and cellular mechanisms underlying anti-neuronal antibody mediated disorders of the central nervous system. Autoimmun Rev 2014, 13:299-312.
44. Brain L., Jellinek E.H., Ball K. Hashimoto's disease and encephalopathy. Lancet 1966, 2:512-514.
45. Mirabelli-Badenier M., Biancheri R., Morana G., et al. Anti-NMDAR encephalitis misdiagnosed as Hashimoto's encephalopathy. Eur J Paediatr Neurol 2014, 18:72-74.
46. Kowal C., Degiorgio L.A., Lee J.Y., et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A 2006, 103:19854-19859.
47. Lapteva L., Nowak M., Yarboro C.H., et al. Anti-N-methyl-d-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 2006, 54:2505-2514.
48. Omdal R., Brokstad K., Waterloo K., Koldingsnes W., Jonsson R., Mellgren S.I. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol 2005, 12:392-398.
49. DeGiorgio L.A., Konstantinov K.N., Lee S.C., Hardin J.A., Volpe B.T., Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001, 7:1189-1193.
50. Flanagan E.P., Caselli R.J. Autoimmune encephalopathy. Semin Neurol 2011, 31:144-157.
51. Graus F., Delattre J.Y., Antoine J.C., et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004, 75:1135-1140.
52. Leypoldt F., Wandinger K.P. Paraneoplastic neurological syndromes. Clin Exp Immunol 2014, 175:336-348.
53. Pollak T.A., McCormack R., Peakman M., Nicholson T.R., David A.S. Prevalence of anti-N-methyl-d-aspartate (NMDA) receptor antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis. Psychol Med 2014, 44:2475-2487.
54. Pearlman D.M., Najjar S. Meta-analysis of the association between N-methyl-d-aspartate receptor antibodies and schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder. Schizophr Res 2014, 157:249-258.
55. Liba Z., Sebronova V., Komarek V., Sediva A., Sedlacek P. Prevalence and treatment of anti-NMDA receptor encephalitis. Lancet Neurol 2013, 12:424-425.
56. Thomas A., Rauschkolb P., Gresa-Arribas N., Schned A., Dalmau J.O., Fadul C.E. Anti-N-methyl-d-aspartate receptor encephalitis: a patient with refractory illness after 25months of intensive immunotherapy. JAMA Neurol 2013, 70:1566-1568.
57. Kruse J.L., Jeffrey J.K., Davis M.C., Dearlove J., IsHak W.W., Brooks J.O. Anti-N-methyl-d-aspartate receptor encephalitis: a targeted review of clinical presentation, diagnosis, and approaches to psychopharmacologic management. Ann Clin Psychiatry 2014, 26:111-119.